These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

835 related articles for article (PubMed ID: 33964002)

  • 1. A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.
    Andersen A; Knop FK; Vilsbøll T
    Drugs; 2021 Jun; 81(9):1003-1030. PubMed ID: 33964002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
    Cowart K
    Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
    [No Abstract]   [Full Text] [Related]  

  • 3. Practical guidance for use of oral semaglutide in primary care: a narrative review.
    Morales J; Shubrook JH; Skolnik N
    Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus
    Miyasaka K
    Nihon Yakurigaku Zasshi; 2022; 157(2):146-154. PubMed ID: 35228448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
    Meier JJ
    Front Endocrinol (Lausanne); 2021; 12():645617. PubMed ID: 34248838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
    Aroda VR; Blonde L; Pratley RE
    Rev Endocr Metab Disord; 2022 Oct; 23(5):979-994. PubMed ID: 35838946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Semaglutide.
    Smits MM; Van Raalte DH
    Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
    Brunton SA; Mosenzon O; Wright EE
    Postgrad Med; 2020 Nov; 132(sup2):48-60. PubMed ID: 32815453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.
    Kaku K; Yamada Y; Watada H; Abiko A; Nishida T; Zacho J; Kiyosue A
    Diabetes Obes Metab; 2018 May; 20(5):1202-1212. PubMed ID: 29322610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
    Kim HS; Jung CH
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
    Gallwitz B; Giorgino F
    Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
    JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].
    Paquot N
    Rev Med Liege; 2021 Dec; 76(12):896-903. PubMed ID: 34881835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
    Tan X; Cao X; Zhou M; Zou P; Hu J
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
    Chun JH; Butts A
    JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
    Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
    Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
    Tuchscherer RM; Thompson AM; Trujillo JM
    Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.